



Figure 2. Schematic representation of the final joint model. F is the bioavailability, D the dose administered, ka the absorption constant, V the volume of distribution, ke the elimination constant, $[AAG]$ the AAG concentration, N_{AAG} the number of binding site on AAG for DRV, K_d the dissociation constant of AAG for DRV, $[HSA]$ the albumin concentration, θ_{HSA} the binding constant of HSA for DRV. AUC_{RTV} the RTV AUC_{0-24h} inhibiting the elimination of DRV.